inPractice® - Integrase Inhibitors, Other ARVs, and Statins

Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/3/19 (What's New)

Summary

Cobicistat/elvitegravir/emtricitabine/tenofovir DF and cobicistat/elvitegravir/emtricitabine/tenofovir AF should not be coadministered with lovastatin or simvastatin^{[FDA COBI/EVG/TDF/FTC; FDA COBI/EVG/TAF/FTC]}
Titrate carefully from the lowest starting dose when coadministering cobicistat/elvitegravir/emtricitabine/tenofovir DF with atorvastatin, not to exceed 20 mg/day^{[FDA COBI/EVG/TDF/FTC; DHHS ART]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Pharmacokinetics